An improved method for the detection of the thermolabile variant of methylenetetrahydrofolate reductase

Clinical Chemistry

Volumn 44, Issue 5, 1998, Pages 1045-1047

  Van Amerongen, Geneviève ^a   Mathonnet, Florence ^a,b   Boucly, Catherine ^a   Mathieu, Bertille ^a   Vinatier, Isabelle ^b   Peltier, Jean Yves ^b   Catherine, Nicole ^b   Collet, Catherine ^c   De Mazancourt, Philippe ^a,d  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b Laboratoires d'Hematologie Ctr H   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^d CJF 9402   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA FRAGMENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FETUS WASTAGE; GENE AMPLIFICATION; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; NEURAL TUBE DEFECT; PHLEBITIS; SICKLE CELL;

EID: 0031949682     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.5.1045     Document Type: Article

References (14)

1. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
2. Nelen WLDM, Steegers EAP, Eskes TKAB, Blom HJ. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet 1997;350:861.
3. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spiina bifida. Lancet 1995;346:1070-1.
4. Fermo I, Vigano' D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.
5. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E. Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
6. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080-3.
7. Brattström L, Tengborn L, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991;21:51-7.
8. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463-9.
9. McAndrew PE, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res 1996;83:195-8.
10. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465-70.
11. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997;349:1591-3.
12. McIndoe RA, Linhardt MS, Hood L. Single-tube genomic DNA isolation from whole blood without pre-isolating white blood cells. BioTechniques 1995; 19:30-3.
13. Pflug W, Mai G, Wahl G, Aab S, Eberspächer B, Keller U. A simple method to prevent inhibition of Taq polymerase and Hinfl restriction enzyme in DNA analysis of stain material. Adv Forensic Haemogenet 1992;4:163-5.
14. Husain SM, Kalavathi P, Anandaraj MP. Analysis of sickle cell gene using polymerase chain reaction and restriction enzyme Bsu 361. Indian J Med Res 1995;101:273-6.